Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data

International Journal of Gynecological Pathology

Volumn 23, Issue 3, 2004, Pages 200-205

  Gilks, C Blake ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

BRCA; Molecular pathology; Ovary; Surface epithelial tumors

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

CANCER GRADING; CLEAR CELL CARCINOMA; CYSTADENOCARCINOMA; ENDOMETRIOID CARCINOMA; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; MUCINOUS CARCINOMA; ONCOGENE; OVARY TUMOR; PRIORITY JOURNAL; REVIEW; TRANSITIONAL CELL CARCINOMA; TUMOR CLASSIFICATION; UNDIFFERENTIATED CARCINOMA;

CARCINOMA; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 3042737680     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pgp.0000130446.84670.93     Document Type: Review

References (58)

1. Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 2000;19:7-15.
2. Shimizu Y, Kamoi S, Amada S, et al. Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features-problems involved in the architectural grading system. Gynecol Oncol 1998;70:2-12.
3. Shimizu Y, Kamoi S, Amada S, et al. Toward the development of an universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 1998;82:893-901.
4. Ishioka S, Sagae S, Terasawa K, et al. Comparison of the usefulness between a new universal grading system for epithelial ovarian cancer and the FIGO grading system. Gynecol Oncol 2003;89:447-52.
5. Mayr D, Diebold J. Grading of ovarian carcinomas. Int J Gynecol Pathol 2000;19:348-53.
6. Sato Y, Shimamoto T, Amada S, et al. Prognostic value of histologic grading of ovarian carcinomas. Int J Gynecol Pathol 2003;22:52-6.
7. Hendrickson MR, Longacre TA. Classification of surface epithelial neoplasms of the ovary. In: Hendrickson MR, ed. Surface Epithelial Neoplasms of the Ovary. Philadelphia: Hanley and Belfus; 1993.
8. Cramer SF, Roth LM, Ulbright TM, et al. Evaluation of the reproducibility of the World Health Organization classification of common ovarian cancers. Arch Pathol Lab Med 1987;111:819-29.
9. Lund B, Thomsen HK, Olsen J. Reproducibility of histopathological evaluation in epithelial ovarian carcinoma. APMIS 1991;99:353-58.
10. Sakamoto A, Sasaki H, Furusato M, et al. Observer disagreement in histological classification of ovarian tumors in Japan. Gynecol Oncol 1994;54:54-8.
11. Seidman JD, Horkayne-Szakaly S, Haiba M, et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 2004;23:41-4.
12. Parker RL, Yorida E, Cheang M, et al. Loss of p16 expression is of prognostic significance in high-grade advanced-stage ovarian cancer. Mod Pathol 2004;17:201A.
13. Armes JE, Venter DJ. The pathology of inherited breast cancer. Pathology (Phila) 2002;34:309-14.
14. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002;20:2310-8.
15. Goffin JR, Chappuis PO, Begin LR, et al. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. Cancer 2003;97:527-36.
16. Narod SA, Boyd J. Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer. Curr Opin Obstet Gynecol 2002;14:19-26.
17. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2002;283:2260-5.
18. Shaw PA, McLaughlin JR, Zweemer RP, et al. Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol 2002;21:407-11.
19. Werness BA, Ramus SJ, DiCioccio RA, et al. Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry. Int J Gynecol Pathol 2004;23:29-34.
20. Jazaeri AA, Yee CJ, Sotiriou C, et al. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst 2002;94:990-1000.
21. Zweemer RP, Shaw PA, Verheijen RM, et al. Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations. J Clin Pathol 1999;52:372-5.
22. Pharoah PD, Easton DF, Stockton DL, et al. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res 1999;59:868-71.
23. Buller RE, Shahin MS, Geisler JP, et al. Failure of BRCA1 dysfunction to alter ovarian cancer survival. Clin Cancer Res 2002;8:1196-202.
24. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000;283:2260-5.
25. Ben David Y, Chetrit A, Hirsh-Yechezkel G, et al. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol 2002;20:463-6.
26. Cass I, Baldwin RL, Varkey T, et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003;97:2127-9.
27. Geisler JP, Hatterman-Zogg MA, Rathe JA, et al. Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst 2002;94:61-7.
28. Hilton JL, Geisler JP, Rathe JA, et al. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 2002;94:1396-406.
29. Hughes-Davies L, Huntsman D, Ruas M, et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 2003;115:523-35.
30. Irving J, Brown L, Magliocco T, et al. Amplification of a novel BRCA2-inactivating gene, EMSY, in high grade ovarian carcinomas. Mod Pathol 2003;16:193A.
31. Pejovic T. Genetic changes in ovarian cancer. Ann Med 1995;27:73-8.
32. Singer G, Kurman RJ, Chang HW, et al. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002;160:1223-8.
33. Singer G, Oldt R 3rd, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003;95:484-6.
34. Singer G, Shih IeM, Truskinovsky A, et al. Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor). Int J Gynecol Pathol 2003;22:37-41.
35. Katabuchi H, Tashiro H, Cho KR, et al. Micropapillary serous carcinoma of the ovary: an immunohistochemical and mutational analysis of p53. Int J Gynecol Pathol 1998;17:54-60.
36. Gilks CB, Alkushi A, Yue JJW, et al. Advanced-stage serous borderline tumors of the ovary: a clinicopathological study of 49 cases. Int J Gynecol Pathol 2003;22:29-36.
37. Jazaeri AA, Lu K, Schmandt R, et al. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol Carcinog 2003;36:53-9.
38. Gilks B, Vanderhyden B, Zhu S, et al. Distinction between serous borderline tumors and serous carcinomas based on mRNA expression profiling. Mod Pathol 2003;16:190A.
39. Parker RL, Clement PB, Chercover DJ, et al. Early recurrence of ovarian serous borderline tumor as high grade carcinoma: a report of two cases. Int J Gynecol Pathol 2004;23:265-272.
40. Crispens MA, Bodurka D, Deavers M, et al. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol 2002;99:3-10.
41. Mok SC, Bell DA, Knapp RC, et al. Mutation of the K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 1993;53:1489-92.
42. Cuatecasas M, Villanueva A, Matias-Guiu X, et al. K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer 1997;79:1581-6.
43. Mandai M, Konishi I, Kuroda H, et al. Heterogeneous distribution of K-ras-mutated epithelia in mucinous ovarian tumors with special reference to histopathology. Hum Pathol 1998;29:34-40.
44. Garrett AP, Lee KR, Colitti CR, et al. K-ras mutation may be an early event in mucinous ovarian tumorigenesis. Int J Gynecol Pathol 2001;20:244-51.
45. Ludwick C, Gilks CB, Miller D, et al. Aggressive behaviour of stage I ovarian mucinous tumors without destructive stromal invasion. Mod Pathol 2004;17:205A.
46. Palacios J, Gamallo C. Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res 1998;58:1344-7.
47. Gamallo C, Palacios J, Moreno G, et al. Beta-catenin expression pattern in stage I and II ovarian carcinomas: relationship with beta-catenin gene mutations, clinicopathologic features, and clinical outcome. Am J Pathol 1999;155:527-36.
48. Wu R, Zhai Y, Fearon ER, et al. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res 2001;61:8247-55.
49. Schwartz DR, Kardia SL, Shedden KA, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 2002;62:4722-9.
50. Schaner ME, Ross DT, Ciaravino G, et al. Gene expression patterns in ovarian carcinomas. Mol Biol Cell 2003;14:4376-86.
51. Tavassoli FA, Devilee P. (Eds). World Health Organization classification of tumors. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003.
52. Silva EG, Robey-Cafferty SS, Smith TL, et al. Ovarian carcinomas with transitional cell carcinoma pattern. Am J Clin Pathol 1990;93:457-65.
53. Robey SS, Silva EG, Gershenson DM, et al. Transitional cell carcinoma in high-grade high-stage ovarian carcinoma. An indicator of favorable response to chemotherapy. Cancer 1989;63:839-47, discussion 1185-7.
54. Gershenson DM, Silva EG, Mitchell MF, et al. Transitional cell carcinoma of the ovary: a matched control study of advanced-stage patients treated with cisplatin-based chemotherapy. Am J Obstet Gynecol 1993;168:1178-85.
55. Hollingsworth HC, Steinberg SM, Silverberg SG, et al. Advanced stage transitional cell carcinoma of the ovary. Hum Pathol 1996;27:1267-72.
56. Costa MJ, Hansen C, Dickerman A, et al. Clinicopathologic significance of transitional cell carcinoma pattern in nonlocalized ovarian epithelial tumors (stages 2-4). Am J Clin Pathol 1998;109:173-80.
57. Logani S, Oliva E, Amin MB, et al. Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers: histogenetic and diagnostic implications. Am J Surg Pathol 2003;27:1434-41.
58. Eichhorn JH, Young RH. Transitional cell carcinoma of the ovary. A study of its morphology in 100 cases. Am J Surg Pathol 2004;28:453-63.